Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 262

1.

Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfected with HIV and hepatitis C virus.

Pineda JA, Caruz A, Rivero A, Neukam K, Salas I, Camacho A, Palomares JC, Mira JA, Martínez A, Roldán C, de la Torre J, Macías J.

Clin Infect Dis. 2010 Oct 1;51(7):788-95. doi: 10.1086/656235.

2.

IL28B gene polymorphisms and viral kinetics in HIV/hepatitis C virus-coinfected patients treated with pegylated interferon and ribavirin.

Rallón NI, Soriano V, Naggie S, Restrepo C, Goldstein D, Vispo E, McHutchison J, Benito JM.

AIDS. 2011 May 15;25(8):1025-33. doi: 10.1097/QAD.0b013e3283471cae.

PMID:
21505315
3.

Baseline serum low-density lipoprotein cholesterol levels predict response to hepatitis C virus therapy in HIV/hepatitis C virus coinfected patients.

del Valle J, Mira JA, de los Santos I, López-Cortés LF, Merino D, Rivero A, Girón JA, Ríos-Villegas MJ, González-Serrano M, Collado A, García-García JA, Pineda JA.

AIDS. 2008 May 11;22(8):923-30. doi: 10.1097/QAD.0b013e3282ff8ad3.

PMID:
18453851
4.

Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C.

Martin-Carbonero L, Nuñez M, Mariño A, Alcocer F, Bonet L, García-Samaniego J, López-Serrano P, Cordero M, Portu J, Soriano V.

AIDS. 2008 Jan 2;22(1):15-21.

PMID:
18090387
6.

Influence of concomitant antiretroviral therapy on the rate of sustained virological response to pegylated interferon plus ribavirin in hepatitis C virus/HIV-coinfected patients.

Pineda JA, Mira JA, Gil Ide L, Valera-Bestard B, Rivero A, Merino D, Girón-González JA, Ríos-Villegas MJ, González-Serrano M, Collado A, García-García JA, Carrillo-Gómez R, López-Cortés LF, Gómez-Mateos J.

J Antimicrob Chemother. 2007 Dec;60(6):1347-54. Epub 2007 Oct 14.

7.

Efficacy of pegylated interferon and ribavirin for retreatment of chronic HCV infection in HIV co-infected patients failing a previous standard interferon-based regimen.

Crespo M, Mira JA, Pineda JA, Van den Eynde E, Ríos-Villegas MJ, Collado A, Girón-González JA, López-Cortés LF, González-Serrano M, Rivero A, Merino D, Esteban JI.

J Antimicrob Chemother. 2008 Oct;62(4):793-6. doi: 10.1093/jac/dkn262. Epub 2008 Jun 21.

8.

Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.

Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-García J, Lazzarin A, Carosi G, Sasadeusz J, Katlama C, Montaner J, Sette H Jr, Passe S, De Pamphilis J, Duff F, Schrenk UM, Dieterich DT; APRICOT Study Group.

N Engl J Med. 2004 Jul 29;351(5):438-50.

9.

Response-guided therapy for chronic hepatitis C virus infection in patients coinfected with HIV: a pilot trial.

Van den Eynde E, Crespo M, Esteban JI, Jardi R, Ribera E, Carbonell J, Rodríguez-Frias F, Falco V, Curran A, Imaz A, Villar del Saz S, Ocaña I, Esteban R, Pahissa A.

Clin Infect Dis. 2009 Apr 15;48(8):1152-9. doi: 10.1086/597470. Erratum in: Clin Infect Dis. 2009 Aug 1;49(3):489.

10.

IL28B and interferon-gamma inducible protein 10 for prediction of rapid virologic response and sustained virologic response in HIV-HCV-coinfected patients.

Payer BA, Reiberger T, Aberle J, Ferenci P, Holzmann H, Rieger A, Peck-Radosavljevic M; Vienna HIV-HCV study group.

Eur J Clin Invest. 2012 Jun;42(6):599-606. doi: 10.1111/j.1365-2362.2011.02623.x. Epub 2011 Nov 25.

PMID:
22117591
11.

Efficacy and safety of pegylated interferon plus ribavirin in HIV and hepatitis C virus-coinfected patients with advanced immunosuppression.

Mira JA, Gutiérrez-Valencia A, Gil Ide L, Merino D, Rivero A, Ríos-Villegas MJ, Delgado M, González-Serrano M, Collado A, Torres-Tortosa M, Omar M, López-Ruz MA, Macías J, Arponen S, Pineda JA.

Clin Infect Dis. 2009 Oct 15;49(8):e84-91. doi: 10.1086/605677.

12.

IL28B polymorphism, pretreatment CXCL10, and HCV RNA levels predict treatment response in racially diverse HIV/HCV coinfected and HCV monoinfected patients.

Zeremski M, Dimova RB, Makeyeva J, Sipley JD, Jacobson IM, Rennert H, Talal AH.

J Acquir Immune Defic Syndr. 2013 May 1;63(1):9-16. doi: 10.1097/QAI.0b013e31828323c1.

PMID:
23274935
13.

Sustained virologic response and IL28B single-nucleotide polymorphisms in patients with chronic hepatitis C treated with pegylated interferon alfa and ribavirin.

Jabłonowska E, Piekarska A, Koślińska-Berkan E, Omulecka A, Szymańska B, Wójcik K.

Acta Biochim Pol. 2012;59(3):333-7. Epub 2012 Aug 27.

14.

Peginterferon vs. interferon in the treatment of different HCV genotype infections in HIV patients.

Zhao S, Cheng D, Liu E, Yu H, Yang H, Xue X, Chu Y.

Eur J Clin Microbiol Infect Dis. 2008 Dec;27(12):1183-92. doi: 10.1007/s10096-008-0557-8. Epub 2008 Jun 17.

PMID:
18560911
15.

Modeling the probability of sustained virological response to therapy with pegylated interferon plus ribavirin in patients coinfected with hepatitis C virus and HIV.

Medrano J, Neukam K, Rallón N, Rivero A, Resino S, Naggie S, Caruz A, Calvino A, Macías J, Benito JM, Sánchez-Piedra C, Vispo E, Barreiro P, McHutchison J, Pineda JA, Soriano V.

Clin Infect Dis. 2010 Nov 15;51(10):1209-16. doi: 10.1086/656811.

16.

Pegylated interferon alpha2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients.

Moreno L, Quereda C, Moreno A, Perez-Elías MJ, Antela A, Casado JL, Dronda F, Mateos ML, Bárcena R, Moreno S.

AIDS. 2004 Jan 2;18(1):67-73.

PMID:
15090831
17.

Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients.

Rallón NI, Naggie S, Benito JM, Medrano J, Restrepo C, Goldstein D, Shianna KV, Vispo E, Thompson A, McHutchison J, Soriano V.

AIDS. 2010 May 15;24(8):F23-9. doi: 10.1097/QAD.0b013e3283391d6d.

PMID:
20389235
18.

Prediction of response to pegylated interferon plus ribavirin in HIV/hepatitis C virus (HCV)-coinfected patients using HCV genotype, IL28B variations, and HCV-RNA load.

Neukam K, Camacho A, Caruz A, Rallón N, Torres-Cornejo A, Rockstroh JK, Macías J, Rivero A, Benito JM, López-Cortés LF, Nattermann J, Gómez-Mateos J, Soriano V, Pineda JA.

J Hepatol. 2012 Apr;56(4):788-94. doi: 10.1016/j.jhep.2011.11.008. Epub 2011 Dec 13.

PMID:
22173157
19.

Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.

Shepherd J, Brodin H, Cave C, Waugh N, Price A, Gabbay J.

Health Technol Assess. 2004 Oct;8(39):iii-iv, 1-125. Review.

20.

Equally poor outcomes to pegylated interferon-based therapy in African Americans and Hispanics with chronic hepatitis C infection.

Satapathy SK, Lingisetty CS, Proper S, Chaudhari S, Williams S.

J Clin Gastroenterol. 2010 Feb;44(2):140-5. doi: 10.1097/MCG.0b013e3181ba9992.

PMID:
19826275
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk